K2 Principal Fund L.P. Buys Shares of 46,193 Kenvue Inc. $KVUE

K2 Principal Fund L.P. bought a new stake in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 46,193 shares of the company’s stock, valued at approximately $797,000.

A number of other large investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Kenvue by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 234,951,484 shares of the company’s stock valued at $4,052,913,000 after buying an additional 1,604,040 shares during the last quarter. State Street Corp lifted its position in Kenvue by 3.5% in the fourth quarter. State Street Corp now owns 118,865,134 shares of the company’s stock valued at $2,050,424,000 after buying an additional 4,063,257 shares during the last quarter. Geode Capital Management LLC lifted its position in Kenvue by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 49,862,574 shares of the company’s stock valued at $856,778,000 after buying an additional 371,322 shares during the last quarter. Norges Bank acquired a new position in Kenvue in the fourth quarter valued at about $756,862,000. Finally, American Century Companies Inc. lifted its position in Kenvue by 22.4% in the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock valued at $601,267,000 after buying an additional 6,781,640 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Up 0.3%

Shares of NYSE:KVUE opened at $18.13 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The firm has a market capitalization of $34.80 billion, a PE ratio of 21.32, a price-to-earnings-growth ratio of 1.38 and a beta of 0.54. The firm’s 50-day moving average is $17.43 and its two-hundred day moving average is $17.53. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 earnings per share. Analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. Kenvue’s dividend payout ratio is 97.65%.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.59% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on KVUE. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Argus raised shares of Kenvue to a “hold” rating in a research report on Friday, March 6th. Canaccord Genuity Group upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. UBS Group decreased their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Finally, Weiss Ratings lowered shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, Kenvue has an average rating of “Hold” and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.